Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.793
Sell
RSI(14)
33.184
Neutral
STOCH(KDJ)(9,3,3)
18.737
Neutral
ATR(14)
3.904
High Vlolatility
CCI(14)
-103.570
Sell
Williams %R
86.706
Oversold
TRIX(12,20)
-0.409
Sell
StochRSI(14)
92.649
Buy
Becton Dickinson and Co
BDX155.920USD
-0.310-0.20%
Close 03/24, 16:00（ET）Quotes delayed by 15 min
32.76BMarket Cap
25.46P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Becton Dickinson and Co
Currency: USD Updated: 2026-03-24Key Insights
Becton Dickinson and Co's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 202.36.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Becton Dickinson and Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Becton Dickinson and Co Highlights
StrengthsRisks
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.84B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 71.28%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 71.28%.
Undervalued
The company’s latest PE is 25.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 268.89M shares, increasing 0.03% quarter-over-quarter.
Held by Ken Fisher
Star Investor Ken Fisher holds 1.35K shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
202.362
Target Price
+31.29%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-24The current financial score of Becton Dickinson and Co is 7.55, ranking 66 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 5.25B, representing a year-over-year increase of 1.63%, while its net profit experienced a year-over-year increase of 26.07%.
Score
Financials
5.76
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.41
Operational Efficiency
7.66
Growth Potential
7.82
Shareholder Returns
8.11
Becton Dickinson and Co's Company Valuation
Currency: USD Updated: 2026-03-24The current valuation score of Becton Dickinson and Co is 7.31, ranking 96 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 25.46, which is 130.00% below the recent high of 58.55 and 1.15% above the recent low of 25.17.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 22/209
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-24The current earnings forecast score of Becton Dickinson and Co is 7.25, ranking 144 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 201.92, with a high of 265.34 and a low of 183.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
202.362
Target Price
+31.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
115
Total
6
Median
9
Average
Company name
Ratings
Analysts
Becton Dickinson and Co
BDX
16
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-24The current price momentum score of Becton Dickinson and Co is 6.59, ranking 124 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 175.19 and the support level at 145.20, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
156.178
Sell
MA10
158.496
Sell
MA20
165.385
Sell
MA50
166.578
Sell
MA100
158.818
Sell
MA200
151.760
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-24The current institutional shareholding score of Becton Dickinson and Co is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 98.17%, representing a quarter-over-quarter decrease of 0.83%. The largest institutional shareholder is The Vanguard, holding a total of 36.52M shares, representing 12.83% of shares outstanding, with 31.90% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
T. Rowe Price Investment Management, Inc.
State Street Investment Management (US)
MFS Investment Management
Geode Capital Management, L.L.C.
Wellington Management Company, LLP
Putnam Investment Management, L.L.C.
ClearBridge Investments, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-24The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Becton Dickinson and Co is 9.33, ranking 11 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Becton Dickinson and Co’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.30
VaR
+2.06%
240-Day Maximum Drawdown
+21.11%
240-Day Volatility
+29.61%
Return
Best Daily Return
60 days
+5.34%
120 days
+5.34%
5 years
+8.86%
Worst Daily Return
60 days
-2.38%
120 days
-2.50%
5 years
-18.13%
Sharpe Ratio
60 days
+0.35
120 days
+0.77
5 years
+0.00
Risk Assessment
Maximum Drawdown
240 days
+21.11%
3 years
+41.76%
5 years
+41.76%
Return-to-Drawdown Ratio
240 days
-0.06
3 years
-0.16
5 years
-0.08
Skewness
240 days
-2.59
3 years
-2.33
5 years
-1.60
Volatility
Realised Volatility
240 days
+29.61%
5 years
+24.05%
Standardised True Range
240 days
+2.26%
5 years
+2.31%
Downside Risk-Adjusted Return
120 days
+191.28%
240 days
+191.28%
Maximum Daily Upside Volatility
60 days
+22.17%
Maximum Daily Downside Volatility
60 days
+18.87%
Liquidity
Average Turnover Rate
60 days
+0.95%
120 days
+0.99%
5 years
--
Turnover Deviation
20 days
+27.42%
60 days
+46.16%
120 days
+51.44%
Peer Comparison
Healthcare Equipment & Supplies
Becton Dickinson and Co
BDX
7.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LeMaitre Vascular Inc
LMAT
8.22 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
WST
8.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
